Figure 1.

High CDYL2 Expression Level in Breast Cancer Is Associated with Poor Prognosis

(A) CDYL2 mRNA expression in breast tumors compared with normal tissues, as derived from the Oncomine database and GEO2R analysis of the indicated GEO datasets.

(B) Paired analysis of CDYL2 mRNA (TCGA, RNA-seq) and protein levels (CPTAC, mass spectrometry) in individual tumor specimen.

(C–E) Kaplan-Meier overall survival (OS) analysis performed from TCGA breast cancer subtypes: ER+/HER2− (C), triple negative (TN) (D), and ER+/HER2+ (E) using best cutoff of CDYL2 expression (high and low). Significance using log rank p value and hazard ratio (CI).